Clinical Trial Search

Primary: Change Form Baseline in WOMAC A Pain Subscale — -11.14; -11.82 cm — p=<0.025

Primary: Summary of Adverse Events — 2; 2; 3; 2 Adverse events

Primary: Change From Baseline in the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score at 1 Year — 23.3; 9.9 scores on a scale — p=<0.01

Primary: Rate of Progression of Joint Space Narrowing — -0.101; -0.125; -0.109 mm/year — p=0.508770

Primary: Change in Cellular Infiltrates From Day 0 to Day 28 — 2; 0; 2; 4 Participants

Primary: Change in Hyaluronate Concentration — 0.29568 mg/ml

Primary: Change in Pain on the VIsual Analog Scale (VAS) — -.068 change in units on a scale from baseline

Primary: Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6 — -23.6; -14.1 mm — p=0.141

Primary: Osteoarthritis Structural Changes Assessed by Quantitative Magnetic Resonance Imaging With and Without Neuropathic Pain — 14; 7; 5; 1 participants

Primary: Percentage of Patients With a Presence of Matrix Metalloproteinase-9 (MMP-9) in the Study Eye — 36.2 percentage of participants

Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale

Primary: Oswestry Disability Index — 41.3; 30.4; 19.4 score on a scale

Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants

Primary: Total Ghent University Scoring System (GUSS) of Target Joints at Week 24 — 162.2; 153.3 units on a scale — p=0.024

Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34

Primary: Number of Participants Experiencing One or More Treatment-Emergent Adverse Event — 28; 33 Participants — p=>0.9

Primary: Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of Treatment — -0.1361; -0.0442; -0.2261; -0.2000…

Primary: Differences in Decision Conflict Scale With ASK vs Usual Care — 25.1; 26.0 Score on a scale

Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants

Primary: Normal Limits of TUVjoint in Healthy Subjects

Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 0 participants

Primary: Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target Knee — 5.8; 5.9 units on a scale

Primary: Pain When Walking On A Flat Surface — 0; 1; 8; 4 Participants

Primary: Facet Joint High Grade FDG Activity Concordance to Pain — 0.10 concordance correlation coefficient

Primary: Change of External Knee Adduction Moment as Assessed by Visual Motion Analysis System — 0.50 Nm/kg

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years

Primary: Change From Baseline in Pain Measured by the VAS Scale — -2.00 units on a scale

Primary: Change at 6 Months From Baseline in First Peak Knee Adduction Moment (KAM): (6 Month Value - Baseline) — -0.19 %Bw*Ht

Primary: Change in Pain Intensity (Numerical Rating Scale NRS, Discrete Boxes 0-10, Higher Score Mean Worse Pain) — -1.30 Units on a scale